Anticoagulation during cardioversion in patients with atrial fibrillation: current clinical practice.
The role of anticoagulation in the long-term treatment of atrial fibrillation (AF) has been well established in prospective randomized trials. Less certainty exists on the optimal anticoagulation in the setting of AF cardioversion. Current guidelines advocate anticoagulation for 3-4 weeks before and after cardioversion of AF of >48 hours' duration. Alternatively, early cardioversion may be performed after exclusion of left atrial thrombi by transesophageal echocardiography. However, with conventional anticoagulation, the risk of bleeding has to be considered and, thus, anticoagulation is frequently underused in the clinical setting. Moreover, the role of cardioversion has been questioned by recent trials suggesting no benefit of sinus rhythm restoration over rate control in AF. This article aims to summarize the currently available data on anticoagulation in cardioversion of AF in the context of these new studies and points to some new drugs such as low-molecular weight heparins and oral thrombin inhibitors that may lead to safer anticoagulation for prevention of thromboembolic complications of AF in the future.
Stellbrink
Christoph
C
Department of Medicine and Cardiology, University of Technology, Aachen, Germany. cstellbrink@t-online.de
Schimpf
Thomas
T
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000628:therapy*; D001777:Blood Coagulation / Q000187:drug effects; D004554:Electric Countershock / Q000379:methods*; D006801:Humans; D017410:Practice Guidelines as Topic; D013997:Time Factors
D000925:Anticoagulants